Login Register Cart 0
Research Article

通过肽微阵列分析慢性肝病和肝细胞癌患者的HCV免疫应答

卷 29, 期 15, 2022

发表于: 12 January, 2022

页: [2736 - 2747] 页: 12

弟呕挨: 10.2174/0929867328666211104093718

价格: $65

摘要

背景：丙型肝炎病毒（HCV）的慢性感染是肝纤维化，肝硬化以及肝细胞癌（HCC）的主要原因之一，并且与发生淋巴组织增生性疾病的显着风险有关。临床疾病进展的速度因多种宿主和病毒因素而异，包括免疫反应。 方法：对HCV相关肝脏或淋巴组织增生性疾病患者的抗HCV抗体进行全面的表位图谱分析，在肽微阵列平台上分析临床样品，该平台由来自整个HCV蛋白质组的5952个重叠的15-mer合成肽组成。我们评估了 71 例被诊断为 HCC、混合型冷球蛋白血症 （MC） 和 HCV 慢性感染的 HCV 阳性患者的抗体谱。在所有HCV阳性患者中检测到针对病毒肽的抗体反应性。重要的是，不同患者群体内部和之间的信号幅度差异很大。 结果：在HCV慢性感染的无症状受试者中，对C肽的抗体反应性普遍较低，在HCC和MC患者中，抗体反应性越来越高。此外，我们发现，与HCV阳性受试者相比，HCC和MC患者对HCV C，E2，NS3，NS4A，NS4B，NS5A和p7的特定结构域的IgG反应具有统计学意义。 结论：综上所述，我们的数据表明，针对特定HCV蛋白结构域的免疫应答可能代表HCV阳性患者疾病进展的有用生物标志物，并表明肽微阵列是临床前HCV研究中免疫治疗靶点筛选的良好工具。

关键词: 肝细胞癌（HCC），混合冷球蛋白血症（MC），丙型肝炎病毒（HCV），肽微阵列，抗体，肽生物标志物，淋巴组织增生性疾病。

« Previous
[1]
Gower, E.; Estes, C.; Blach, S.; Razavi-Shearer, K.; Razavi, H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol., 2014, 61(1)(Suppl.), S45-S57.
[http://dx.doi.org/10.1016/j.jhep.2014.07.027] [PMID: 25086286]
[2]
Mohd Hanafiah, K.; Groeger, J.; Flaxman, A.D.; Wiersma, S.T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology, 2013, 57(4), 1333-1342.
[http://dx.doi.org/10.1002/hep.26141] [PMID: 23172780]
[3]
Razavi, H.; Sanchez Gonzalez, Y.; Yuen, C.; Cornberg, M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int., 2020, 40(3), 522-529.
[http://dx.doi.org/10.1111/liv.14324] [PMID: 31815353]
[4]
Cox, A.L. MEDICINE. Global control of hepatitis C virus. Science, 2015, 349(6250), 790-791.
[http://dx.doi.org/10.1126/science.aad1302] [PMID: 26293940]
[5]
Thomas, D.L. Global elimination of chronic hepatitis. N. Engl. J. Med., 2019, 380(21), 2041-2050.
[http://dx.doi.org/10.1056/NEJMra1810477] [PMID: 31116920]
[6]
Sulkowski, M.S.; Gardiner, D.F.; Rodriguez-Torres, M.; Reddy, K.R.; Hassanein, T.; Jacobson, I.; Lawitz, E.; Lok, A.S.; Hinestrosa, F.; Thuluvath, P.J.; Schwartz, H.; Nelson, D.R.; Everson, G.T.; Eley, T.; Wind-Rotolo, M.; Huang, S.P.; Gao, M.; Hernandez, D.; McPhee, F.; Sherman, D.; Hindes, R.; Symonds, W.; Pasquinelli, C.; Grasela, D.M. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med., 2014, 370(3), 211-221.
[http://dx.doi.org/10.1056/NEJMoa1306218] [PMID: 24428467]
[7]
Ahmed, K.T.; Almashhrawi, A.A.; Ibdah, J.A.; Tahan, V. Is the 25-year hepatitis C marathon coming to an end to declare victory? World J. Hepatol., 2017, 9(21), 921-929.
[http://dx.doi.org/10.4254/wjh.v9.i21.921] [PMID: 28824743]
[8]
Garcia, A.; Fernandez, S.; Toro, F.; De Sanctis, J.B. An overview of hepatitis C vaccines. Recent Pat. Inflamm. Allergy Drug Discov., 2014, 8(2), 85-91.
[http://dx.doi.org/10.2174/1872213X08666140704115149] [PMID: 25000932]
[9]
Tabata, K.; Neufeldt, C.J.; Bartenschlager, R.; Hepatitis, C. Virus replication. Cold Spring Harb. Perspect. Med., 2020, 10(3)a037093
[http://dx.doi.org/10.1101/cshperspect.a037093] [PMID: 31570388]
[10]
Saik, O.V.; Ivanisenko, T.V.; Demenkov, P.S.; Ivanisenko, V.A. Interactome of the hepatitis C virus: Literature mining with ANDSys-tem. Virus Res., 2016, 218, 40-48.
[http://dx.doi.org/10.1016/j.virusres.2015.12.003] [PMID: 26673098]
[11]
Banerjee, A.; Ray, R.B.; Ray, R. Oncogenic potential of hepatitis C virus proteins. Viruses, 2010, 2(9), 2108-2133.
[http://dx.doi.org/10.3390/v2092108] [PMID: 21994721]
[12]
Harris, H.J.; Davis, C.; Mullins, J.G.; Hu, K.; Goodall, M.; Farquhar, M.J.; Mee, C.J.; McCaffrey, K.; Young, S.; Drummer, H.; Balfe, P.; McKeating, J.A. Claudin association with CD81 defines hepatitis C virus entry. J. Biol. Chem., 2010, 285(27), 21092-21102.
[http://dx.doi.org/10.1074/jbc.M110.104836] [PMID: 20375010]
[13]
Major, M.E.; Dahari, H.; Mihalik, K.; Puig, M.; Rice, C.M.; Neumann, A.U.; Feinstone, S.M. Hepatitis C virus kinetics and host re-sponses associated with disease and outcome of infection in chimpanzees. Hepatology, 2004, 39(6), 1709-1720.
[http://dx.doi.org/10.1002/hep.20239] [PMID: 15185313]
[14]
Wieland, S.; Makowska, Z.; Campana, B.; Calabrese, D.; Dill, M.T.; Chung, J.; Chisari, F.V.; Heim, M.H. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology, 2014, 59(6), 2121-2130.
[http://dx.doi.org/10.1002/hep.26770] [PMID: 24122862]
[15]
Liang, Y.; Shilagard, T.; Xiao, S.Y.; Snyder, N.; Lau, D.; Cicalese, L.; Weiss, H.; Vargas, G.; Lemon, S.M. Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology, 2009, 137(4), 1448-1458.
[http://dx.doi.org/10.1053/j.gastro.2009.07.050] [PMID: 19632233]
[16]
Netski, D.M.; Mosbruger, T.; Depla, E.; Maertens, G.; Ray, S.C.; Hamilton, R.G.; Roundtree, S.; Thomas, D.L.; McKeating, J.; Cox, A. Humoral immune response in acute hepatitis C virus infection. Clin. Infect. Dis., 2005, 41(5), 667-675.
[http://dx.doi.org/10.1086/432478] [PMID: 16080089]
[17]
Dustin, L.B.; Charles, E.D. Primary, post-primary and non-specific immunoglobulin M responses in HCV infection. Antivir. Ther., 2012, 17(7 Pt B), 1449-1452.
[http://dx.doi.org/10.3851/IMP2222] [PMID: 23322600]
[18]
Westbrook, R.H.; Dusheiko, G. Natural history of hepatitis C. J. Hepatol., 2014, 61(1)(Suppl.), S58-S68.
[http://dx.doi.org/10.1016/j.jhep.2014.07.012] [PMID: 25443346]
[19]
Cacoub, P.; Comarmond, C.; Domont, F.; Savey, L.; Desbois, A.C.; Saadoun, D. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther. Adv. Infect. Dis., 2016, 3(1), 3-14.
[http://dx.doi.org/10.1177/2049936115585942] [PMID: 26862398]
[20]
Roccatello, D.; Saadoun, D.; Ramos-Casals, M.; Tzioufas, A.G.; Fervenza, F.C.; Cacoub, P.; Zignego, A.L.; Ferri, C. Cryoglobulinae-mia. Nat. Rev. Dis. Primers, 2018, 4(1), 11.
[http://dx.doi.org/10.1038/s41572-018-0009-4] [PMID: 30072738]
[21]
Brasher, N.A.; Eltahla, A.A.; Underwood, A.; Boo, I.; Rizzetto, S.; Walker, M.R.; Rodrigo, C.; Luciani, F.; Maher, L.; Drummer, H.E.; Tedla, N.; Lloyd, A.R.; Bull, R.A. B cell immunodominance in primary hepatitis C virus infection. J. Hepatol., 2020, 72(4), 670-679.
[http://dx.doi.org/10.1016/j.jhep.2019.11.011] [PMID: 31785346]
[22]
Edmondson, H.A.; Steiner, P.E. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer, 1954, 7(3), 462-503.
[http://dx.doi.org/10.1002/1097-0142(195405)7:3<462:AID-CNCR2820070308>3.0.CO;2-E] [PMID: 13160935]
[23]
Stephenson, K.E.; Neubauer, G.H.; Reimer, U.; Pawlowski, N.; Knaute, T.; Zerweck, J.; Korber, B.T.; Barouch, D.H. Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. J. Immunol. Methods, 2015, 416, 105-123.
[http://dx.doi.org/10.1016/j.jim.2014.11.006] [PMID: 25445329]
[24]
Frank, R. The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports--principles and applications. J. Immunol. Methods, 2002, 267(1), 13-26.
[http://dx.doi.org/10.1016/S0022-1759(02)00137-0] [PMID: 12135797]
[25]
Pezzuto, F.; Izzo, F.; Buonaguro, L.; Annunziata, C.; Tatangelo, F.; Botti, G.; Buonaguro, F.M.; Tornesello, M.L. Tumor specific muta-tions in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma. Oncotarget, 2016, 7(34), 54253-54262.
[http://dx.doi.org/10.18632/oncotarget.9801] [PMID: 27276713]
[26]
Pezzuto, F.I.F.; De Luca, P.; Biffali, E.; Buonaguro, L.; Tatangelo, F.; Buonaguro, F.M.; Tornesello, M.L. Clinical significance of te-lomerase reverse-transcriptase promoter mutations in hepatocellular carcinoma. Cancers (Basel), 2021, 15(13), 13.
[27]
Zhang, P.; Zhong, L.; Struble, E.B.; Watanabe, H.; Kachko, A.; Mihalik, K.; Virata, M.L.; Alter, H.J.; Feinstone, S.; Major, M. Deple-tion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activi-ty. Proc. Natl. Acad. Sci. USA, 2009, 106(18), 7537-7541.
[http://dx.doi.org/10.1073/pnas.0902749106] [PMID: 19380744]
[28]
Keck, Z.; Wang, W.; Wang, Y.; Lau, P.; Carlsen, T.H.; Prentoe, J.; Xia, J.; Patel, A.H.; Bukh, J.; Foung, S.K. Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycopro-tein. J. Virol., 2013, 87(1), 37-51.
[http://dx.doi.org/10.1128/JVI.01941-12] [PMID: 23097455]
[29]
Morin, T.J.; Broering, T.J.; Leav, B.A.; Blair, B.M.; Rowley, K.J.; Boucher, E.N.; Wang, Y.; Cheslock, P.S.; Knauber, M.; Olsen, D.B.; Ludmerer, S.W.; Szabo, G.; Finberg, R.W.; Purcell, R.H.; Lanford, R.E.; Ambrosino, D.M.; Molrine, D.C.; Babcock, G.J. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog., 2012, 8(8)e1002895
[http://dx.doi.org/10.1371/journal.ppat.1002895] [PMID: 22952447]
[30]
Tarr, A.W.; Urbanowicz, R.A.; Ball, J.K. The role of humoral innate immunity in hepatitis C virus infection. Viruses, 2012, 4(1), 1-27.
[http://dx.doi.org/10.3390/v4010001] [PMID: 22355450]
[31]
Deng, Y.; Guan, J.; Wen, B.; Zhu, N.; Chen, H.; Song, J.; Yang, Y.; Wang, Y.; Tan, W. Induction of broadly neutralising HCV anti-bodies in mice by integration-deficient lentiviral vector-based pseudotyped particles. PLoS One, 2013, 8(4)e62684
[http://dx.doi.org/10.1371/journal.pone.0062684] [PMID: 23626846]
[32]
Courouce, A.M.; Bouchardeau, F.; Girault, A.; Le Marrec, N. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet, 1994, 343(8901), 853-854.
[http://dx.doi.org/10.1016/S0140-6736(94)92054-0] [PMID: 7511195]
[33]
Grebely, J.; Raffa, J.D.; Lai, C.; Krajden, M.; Conway, B.; Tyndall, M.W. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can. J. Gastroenterol., 2007, 21(7), 447-451.
[http://dx.doi.org/10.1155/2007/796325] [PMID: 17637948]
[34]
Ferroni, P.; Mascolo, G.; Zaninetti, M.; Colzani, D.; Pregliasco, F.; Pirisi, M.; Barbone, F.; Gasparini, V. Identification of four epitopes in hepatitis C virus core protein. J. Clin. Microbiol., 1993, 31(6), 1586-1591.
[http://dx.doi.org/10.1128/jcm.31.6.1586-1591.1993] [PMID: 7686184]
[35]
El Awady, M.K.; El-Demellawy, M.A.; Khalil, S.B.; Galal, D.; Goueli, S.A. Synthetic peptide-based immunoassay as a supplemental test for HCV infection. Clin. Chim. Acta, 2002, 325(1-2), 39-46.
[http://dx.doi.org/10.1016/S0009-8981(02)00245-0] [PMID: 12367764]
[36]
Sällberg, M.; Rudén, U.; Wahren, B.; Magnius, L.O. Antigenic regions within the hepatitis C virus envelope 1 and non-structural pro-teins: identification of an IgG3-restricted recognition site with the envelope 1 protein. Clin. Exp. Immunol., 1993, 91(3), 489-494.
[http://dx.doi.org/10.1111/j.1365-2249.1993.tb05929.x] [PMID: 7680297]
[37]
Sällberg, M.; Rudén, U.; Wahren, B.; Magnius, L.O. Immunodominant regions within the hepatitis C virus core and putative matrix proteins. J. Clin. Microbiol., 1992, 30(8), 1989-1994.
[http://dx.doi.org/10.1128/jcm.30.8.1989-1994.1992] [PMID: 1380007]
[38]
Gopal, R.; Jackson, K.; Tzarum, N.; Kong, L.; Ettenger, A.; Guest, J.; Pfaff, J.M.; Barnes, T.; Honda, A.; Giang, E.; Davidson, E.; Wil-son, I.A.; Doranz, B.J.; Law, M. Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput muta-genesis. PLoS Pathog., 2017, 13(12)e1006735
[http://dx.doi.org/10.1371/journal.ppat.1006735] [PMID: 29253863]
[39]
Atoom, A.M.; Taylor, N.G.; Russell, R.S. The elusive function of the hepatitis C virus p7 protein. Virology, 2014, 462-463, 377-387.
[http://dx.doi.org/10.1016/j.virol.2014.04.018] [PMID: 25001174]
[40]
Sakai, A.; Claire, M.S.; Faulk, K.; Govindarajan, S.; Emerson, S.U.; Purcell, R.H.; Bukh, J. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc. Natl. Acad. Sci. USA, 2003, 100(20), 11646-11651.
[http://dx.doi.org/10.1073/pnas.1834545100] [PMID: 14504405]
[41]
Liu, J.; Tang, W.; Budhu, A.; Forgues, M.; Hernandez, M.O.; Candia, J.; Kim, Y.; Bowman, E.D.; Ambs, S.; Zhao, Y.; Tran, B.; Wu, X.; Koh, C.; Surana, P.; Liang, T.J.; Guarnera, M.; Mann, D.; Rajaure, M.; Greten, T.F.; Wang, Z.; Yu, H.; Wang, X.W. A viral expo-sure signature defines early onset of hepatocellular carcinoma. Cell, 2020, 182(2), 317-328.
[http://dx.doi.org/10.1016/j.cell.2020.05.038] [PMID: 32526205]
[42]
Xu, G.J.; Kula, T.; Xu, Q.; Li, M.Z.; Vernon, S.D.; Ndung’u, T.; Ruxrungtham, K.; Sanchez, J.; Brander, C.; Chung, R.T.; O’Connor, K.C.; Walker, B.; Larman, H.B.; Elledge, S.J. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. Science, 2015, 348(6239), aaa0698.
[http://dx.doi.org/10.1126/science.aaa0698] [PMID: 26045439]

Rights & Permissions Print Cite
Article Metrics
25
1
© 2024 Bentham Science Publishers | Privacy Policy